tiprankstipranks
Advertisement
Advertisement

KROS Stock Latest News

Keros Therapeutics’ TROPOS Trial Termination: What It Means for KROS Investors
Company AnnouncementsKeros Therapeutics’ TROPOS Trial Termination: What It Means for KROS Investors
10d ago
KROS
Keros Therapeutics Appoints Anne Prener to Board
PremiumCompany Announcements
Keros Therapeutics Appoints Anne Prener to Board
16d ago
8K
KROS
Keros Therapeutics Stockholders Approve Directors and Governance Matters
PremiumCompany Announcements
Keros Therapeutics Stockholders Approve Directors and Governance Matters
1M ago
8K
KROS
Keros Therapeutics CEO to Present at Goldman Sachs Conference
PremiumCompany Announcements
Keros Therapeutics CEO to Present at Goldman Sachs Conference
1M ago
8K
KROS
Hold Rating Reiterated on Keros as Takeda Partnership Progress Offsets Rinvatercept Delays; $16 Price Target Maintained
PremiumRatings
Hold Rating Reiterated on Keros as Takeda Partnership Progress Offsets Rinvatercept Delays; $16 Price Target Maintained
2M ago
KROS
Keros Therapeutics: Buy Rating Reaffirmed on Rinvatercept-Focused Strategy and Unchanged $20 Price Target
PremiumRatingsKeros Therapeutics: Buy Rating Reaffirmed on Rinvatercept-Focused Strategy and Unchanged $20 Price Target
2M ago
KROS
Keros Therapeutics reports Q1 EPS ($1.21), consensus (92c)
Premium
The Fly
Keros Therapeutics reports Q1 EPS ($1.21), consensus (92c)
2M ago
KROS
Balanced Hold on Keros as Rinvatercept Progress Offsets Execution and Timeline Risks
Premium
Ratings
Balanced Hold on Keros as Rinvatercept Progress Offsets Execution and Timeline Risks
4M ago
KROS
Keros Therapeutics Advances Rinvatercept in ALS Collaboration
PremiumCompany Announcements
Keros Therapeutics Advances Rinvatercept in ALS Collaboration
4M ago
8K
KROS
Keros Therapeutics announces collaboration with Sean M. Healey & AMG Center
PremiumThe Fly
Keros Therapeutics announces collaboration with Sean M. Healey & AMG Center
4M ago
KROS
Keros Therapeutics presents additional data from Phase 1 of rinvatercept
PremiumThe Fly
Keros Therapeutics presents additional data from Phase 1 of rinvatercept
4M ago
KROS
Keros Therapeutics’ Smaller Reporting Status Cuts Disclosure Burden but May Weigh on Investor Appeal and Volatility
PremiumCompany Announcements
Keros Therapeutics’ Smaller Reporting Status Cuts Disclosure Burden but May Weigh on Investor Appeal and Volatility
4M ago
KROS
Keros Therapeutics price target lowered to $20 from $23 at Wells Fargo
PremiumThe FlyKeros Therapeutics price target lowered to $20 from $23 at Wells Fargo
4M ago
KROS
Keros Highlights Rinvatercept Strategy in Updated Investor Presentation
Premium
Company Announcements
Keros Highlights Rinvatercept Strategy in Updated Investor Presentation
4M ago
8K
KROS
KROS Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
KROS Upcoming Earnings Report: What to Expect?
4M ago
KROS
Keros Therapeutics Adds Veteran Finance Leader to Board
PremiumCompany Announcements
Keros Therapeutics Adds Veteran Finance Leader to Board
5M ago
8K
KROS
Keros Therapeutics CEO to Present at Multiple Conferences
PremiumCompany Announcements
Keros Therapeutics CEO to Present at Multiple Conferences
5M ago
8K
KROS
Keros Therapeutics Highlights Rinvatercept Strategy in Updated Presentation
PremiumCompany Announcements
Keros Therapeutics Highlights Rinvatercept Strategy in Updated Presentation
6M ago
8K
KROS
Largest borrow rate increases among liquid names
PremiumThe Fly
Largest borrow rate increases among liquid names
7M ago
NNE
ABTC
Keros Therapeutics price target raised to $19 from $18 at BofA
PremiumThe FlyKeros Therapeutics price target raised to $19 from $18 at BofA
8M ago
KROS
Keros Therapeutics price target raised to $27 from $23 at Oppenheimer
Premium
The Fly
Keros Therapeutics price target raised to $27 from $23 at Oppenheimer
8M ago
KROS
Keros Therapeutics price target raised to $27 from $23 at Oppenheimer
Premium
The Fly
Keros Therapeutics price target raised to $27 from $23 at Oppenheimer
8M ago
KROS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >